[123]
Prothonotary Milczynski makes a specific finding on the evidence that there are "limited" exceptions where Novopharm has discharged the onus, and her reference to the acknowledgment of counsel in the final paragraph is not the basis for the finding that "Novopharm has not established to my satisfaction that all the materials in the ANDS should be treated as confidential, the only exceptions being information about the comparative bioequivalence of Novopharm's 15 mg and 30 mg delayed-release capsules, and the specific formulation of the capsules' non-medicinal ingredients ... ."